Methods and compositions for treating multiple sclerosis and related disorders
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
A61K-047/69
A61K-047/64
A61K-047/60
출원번호
US-0433898
(2017-02-15)
등록번호
US-10080808
(2018-09-25)
발명자
/ 주소
Santamaria, Pedro
출원인 / 주소
UTI LIMITED PARTNERSHIP
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
46
초록▼
This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sc
This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.
대표청구항▼
1. A method for expanding or developing anti-inflammatory T-cells specific for a multiple sclerosis related-antigen in a subject comprising administering to the subject an effective amount of a nanoparticle complex comprising: a nanoparticle core and multiple sclerosis-related antigen-MHC class II p
1. A method for expanding or developing anti-inflammatory T-cells specific for a multiple sclerosis related-antigen in a subject comprising administering to the subject an effective amount of a nanoparticle complex comprising: a nanoparticle core and multiple sclerosis-related antigen-MHC class II protein (pMHCII) complexes operatively coupled to the nanoparticle core, wherein the nanoparticle core has a diameter from about 1 nm to about 100 nm and wherein the pMHCII density on the nanoparticle core comprises from about 0.005 pMHCII/100 nm2 to about 25 pMHCII/100 nm2. 2. The method of claim 1, wherein the nanoparticle core has a biodegradable layer on the outer surface of the nanoparticle core and the pMHCII complexes are operatively coupled to the nanoparticle core or the biodegradable layer on the nanoparticle core. 3. The method of claim 1 or 2, wherein the multiple sclerosis-related antigen of the pMHCII complexes is an antigen derived from a protein selected from the group of myelin basic protein, myelin associated glycoprotein, myelin oligodendrocyte protein, proteolipid protein, oligodendrocyte myelin oligoprotein, myelin associated oligodendrocyte basic protein, oligodendrocyte specific protein, heat shock proteins, oligodendrocyte specific proteins NOGO A, glycoprotein Po, peripheral myelin protein 22, and 2′3′-cyclic nucleotide 3′-phosphodiesterase and myelin oligodendrocyte glycoprotein (MOG) or an antigen corresponding to a peptide having at least 80% identity to a peptide comprising the sequence of SEQ ID NO: 1, 4, or 5. 4. The method of claim 1 or 2, wherein the nanoparticle core is non-liposomal. 5. The method of claim 1 or 2, wherein the nanoparticle core comprises a metal, a metal oxide, a metal sulfide, a metal selenide, a magnetic material, a polymer, iron, iron oxide, or gold. 6. The method of claim 2, wherein the biodegradable layer comprises one or more of dextran, mannitol, or poly(ethylene glycol). 7. The method of claim 1, wherein the pMHCII complexes are covalently linked or non-covalently linked to the nanoparticle core. 8. The method of claim 2, wherein the pMHCII complexes are covalently linked or non-covalently linked to the nanoparticle core or the biodegradable layer. 9. The method of claim 1, wherein the pMHCII complexes are covalently linked to the nanoparticle core through a linker less than 5 kD in size. 10. The method of claim 2, wherein the pMHCII complexes are covalently linked to the nanoparticle core or the biodegradable layer through a linker less than 5 kD in size. 11. The method of claim 9 or 10, wherein the linker comprises polyethylene glycol. 12. The method of claim 1 or 2, wherein the nanoparticle core is bioabsorbable and/or biodegradable. 13. The method of claim 1, wherein the MHCII protein of the pMHCII complexes comprises all or part of a HLA-DR, HLA-DQ, or HLA-DP protein. 14. The method of claim 1 or 2, wherein the ratio of the number of pMHCII complexes to the nanoparticle core is from about 10:1 to about 500:1. 15. The method of claim 1 or 2, wherein the nanoparticle core has a diameter from about 1 nm to about 50 nm. 16. The method of claim 1 or 2, wherein the nanoparticle core has a diameter from about 1 nm to about 20 nm. 17. The method of claim 1 or 2, wherein the nanoparticle core has a diameter from about 5 nm to about 20 nm. 18. The method of claim 1, wherein the subject is a mammal. 19. The method of claim 3, wherein the multiple sclerosis-related antigen comprises a polypeptide sequence identical to that set-forth in any one of SEQ ID NOs: 1, 4, or 5. 20. The method of claim 1, wherein the anti-inflammatory T-cells are CD4+ T cells.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (46)
Blattler Walter A. (Brookline MA) Lambert John M. (Brookline MA) Senter Peter D. (Jamaica Plain MA), Acid-cleavable compound, use in protein conjugates and drug delivery systems.
Hershberg,Robert M.; Hosken,Nancy Ann; Lodes,Michael J.; Mohamath,Raodoh, Compositions and methods for the therapy and diagnosis of inflammatory bowel disease.
Yatvin Milton B. (Portland OR) Stowell Michael H. B. (Pasadena CA) Gallicchio Vincent S. (Lexington KY) Meredith Michael J. (Lake Oswego OR), Covalent microparticle-drug conjugates for biological targeting.
Braun,Jonathan; Cohavy,Offer, Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens.
Gordon Julian (Arlesheim CHX) Staehelin Theophil (Arlesheim CHX) Towbin Harry (Allschwil CHX), Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays.
Konigsberg Paula J. (Pasadena CA) Richer Leroy L. (San Gabriel CA) Schmidt Paul G. (San Marino CA) Uliana Joseph A. (Sierra Madres CA), Liposome targeting using receptor specific ligands.
Tetelman Bruce (Fort Lee NJ) Milios Yannis (New York NY) Park Il-Pyung (Palisades Park NJ) Recht Tom (Forest Hills NY), Point-of-sale terminal for laundry or dry cleaning establishments.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Platzek Johannes (Berlin DEX) Niedballa Ulrich (Berlin DEX) Radeuchel Bernd (Berlin DEX), Process for the production of DTPA-tetraesters of terminal carboxylic acids.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.